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ABSTRACT 
 
Background. It can be a diagnostic challenge to identify COVID-19 patients without 
bacterial co-infection in whom antibiotics can be safely stopped. We sought to evaluate the 
validity of a guideline that recommends withholding antibiotics in patients with a low serum 
procalcitonin (PCT). 
Methods. We retrospectively collected 28-day outcome data on patients admitted to 
Sheffield Teaching Hospitals NHS Foundation Trust, UK, between 5 March and 15 April 
2020, with a positive SARS-CoV-2 polymerase chain reaction (PCR) and PCT within 48 
hours of diagnosis. PCT was considered negative if ≤0.25ng/ml and positive if >0.25ng/ml. 
Primary outcomes included antibiotic consumption, mortality, intensive care admission and 
length of hospital stay. 
Results. 368 patients met the inclusion criteria; 218 (59%) had a negative PCT and 150 
(41%) positive. At 48 hours post-diagnosis, 73 (33%) of those with a negative PCT were 
receiving antimicrobials compared to 126 (84%) with a positive PCT (p<0.001), with a 
corresponding reduction in antimicrobial usage over 28 days (median DDD of 3.0 vs 6.8 
(p<0.001); median DOT 2 vs 5 days (p<0.001) between the negative and positive PCT 
groups.) In the negative PCT group, there were fewer deaths (62 (28%) vs. 54 (36%), 
(p=0.021)) and critical care admissions (19 (9%) vs. 28 (19%), (p=0.007)) than in the positive 
PCT group. Median length of hospital stay was 8.7 and 9 days in the negative and positive 
PCT groups respectively. 
Conclusions. Procalcitonin is a valuable tool in the assessment of patients with SARS-CoV-
2 infection, safely reducing the potential burden of unnecessary antibiotic usage. 
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BACKGROUND 
In patients with COVID-19, the presentation of fever, tachypnoea and hypoxia, together with 
lung infiltrates on chest imaging and a frequent rise in biomarkers such as C-reactive protein 
(CRP) [1] presents a challenge to rational use of antimicrobials, as it is difficult to confidently 
identify or exclude bacterial co-infection. Rates of true bacterial co-infection are estimated to 
be only 7 to 14% [2-4]. Despite this, the International Severe Acute Respiratory and 
emerging Infections Consortium (ISARIC) World Health Organization (WHO) Clinical 
Characterisation Protocol UK (CCP-UK) study has shown that over 80% of patients with 
COVID-19 receive antibiotic treatment [5]. The Surviving Sepsis Campaign recommends 
empiric antibacterial therapy in its guidelines for the management of COVID-19 in critically ill 
adults [6] and the National Institutes of Health treatment guidelines suggest that, in the 
absence of evidence to the contrary, some expert clinicians advise administration of broad 
spectrum antimicrobials to all patients with moderate or severe hypoxia [7]. Unnecessary 
antibiotic usage could result in prolonged inpatient stay and adverse effects and optimising 
antibiotic use is part of national and global efforts to reduce the spread of antimicrobial 
resistance [8, 9]. Strategies to accurately identify patients with COVID-19 who do not have 
bacterial co-infection are urgently required [10]. Recent National Institute for Health and 
Care Excellence (NICE) guidance on pneumonia in the context of COVID-19 has 
recommended further research into the use of procalcitonin (PCT) for this purpose [4]. 
Furthermore, the co-chairs of the American Thoracic Society and Infectious Diseases 
Society of America Guideline for Treatment of Adults with Community Acquired Pneumonia 
(ATS) have endorsed the use of the assay to guide antibiotic usage [11]. 
Unlike other biomarkers such as CRP, PCT is not thought to be routinely raised in COVID-19 
[12-15], although data on its utility in this context are scarce. A recent meta-analysis showed 
that COVID-19 patients with increased PCT values had a nearly 5-fold higher risk of severe 
infection, thought to be due to the presence of bacterial co-infection [16]. PCT has been 
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shown to have a greater impact on antibiotic exposure than standard stewardship strategies 
alone [17], however this hypothesis remains untested in the setting of COVID-19. We set out 
to evaluate whether PCT use had an impact on i) antibiotic usage and ii) outcomes in 
patients with confirmed COVID-19 at a large NHS Foundation Trust Hospital in the United 
Kingdom (UK). 
 
METHODS 
Study Design, Study Site and Population 
This retrospective observational study was undertaken at two sites of Sheffield Teaching 
Hospitals NHS Foundation Trust (STHNHFT; Royal Hallamshire Hospital and Northern 
General Hospital) with a combined total of 1700 beds. Patients diagnosed between 5 March 
and 15 April 2020 were included in the study, allowing assessment of 28-day outcome in all 
patients by the time of analysis. Those diagnosed prior to 5th March were excluded as at 
that stage COVID-19 was managed as a high consequence infectious disease and patients 
were admitted regardless of symptom severity, making the group unrepresentative of those 
admitted later in the epidemic. The enrolment end date of 15th April was before mandatory 
SARS-CoV-2 screening of all patients admitted to hospital was introduced.  
Eligible patients were aged ≥ 18 years old, admitted to STHNFT, with both a positive SARS-
CoV-2 reverse-transcriptase polymerase chain reaction (RT-PCR) result on nose and/or 
throat swabs and/or deep respiratory samples, and a PCT assay undertaken within 48 hours 
of collection of the SARS-CoV-2 sample. RT-PCR was performed using an in-house assay 
targeting E and RdRP genes [18]. Patients with both community and nosocomial acquisition 
of COVID-19 were included. STHNFT guidelines recommended that antibiotics could be 
withheld in COVID-19 patients with a PCT value of ≤0.25ng/ml unless felt necessary by a 
senior clinician, as concomitant bacterial infection is unlikely in such patients [19].  
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The study was granted approval by the STHNFT Clinical Effectiveness Unit (Ref: 9863) 
Data Collection and Outcomes 
Demographic and clinical characteristics of patients were drawn from existing laboratory, 
pharmacy and clinical databases and from examination of physical and electronic patient 
notes. Data were entered into an electronic case report form (Access 2010, Microsoft, 
Redmond, WA, USA) including age, sex, ethnicity, height, weight, comorbidities, and 
antibiotic allergies. 
28-day outcome was recorded as discharged, still in hospital or died. Data on readmissions 
was also collected and the duration of readmissions up to day 28 was incorporated into 
length of stay data for each patient. Adverse events within the 28 days of follow up were 
recorded including: Hospital-acquired pneumonia/ventilator-associated pneumonia 
(HAP/VAP), Clostridioides difficile infection, Meticillin-resistant Staphylococcus aureus 
(MRSA) acquisition and isolation of an extended-spectrum beta-lactamase (ESBL) or AmpC 
beta-lactamase producing organism from a clinical sample. HAP/VAP was defined as 
commencement of a new antibacterial agent for a presumed chest source at least 48 hours 
after COVID-19 diagnosis, in conjunction with either new elevation of white blood cell count 
or neutrophils or positive sputum culture for an organism other than low virulence oral flora. 
This definition was used as other components of the Infectious Diseases Society of America 
(IDSA)/ American Thoracic Society (ATS) definition of HAP/VAP (new lung infiltrates, fever 
and decline in oxygenation) would be difficult to discern in the context of COVID-19 [20]. 
Antibiotic usage was recorded for the 28-day follow up period including antibiotic agent, 
duration, and WHO defined daily doses (DDD). Where different DDDs are defined for oral 
and parenteral preparations, the parenteral figure was used for calculations to avoid 
inappropriate weighting by route of administration for some commonly used agents (e.g. 
clarithromycin) which would not be relevant from a stewardship perspective [21]. Prescribing 
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rates were calculated using DDD/evaluable day for which data of patients who died during 
the 28-day follow up period were censored from the date of death. Days of treatment (DOT) 
were defined as the number of days in the 28-day period for which antibiotics were 
prescribed. 
Statistical Analysis:  
All values from patients meeting eligibility criteria were summarised using the most 
appropriate form, either using frequency/percentages, or medians with IQR (Inter-Quartile 
Range). In the scenario where there are multiple zeros values, and the IQR becomes 
uninformative with values of 0.00 to 0.00, the 10th and 90th centile are reported instead. 
Differences between demographics were analysed with the suitable significance test, 
depending on whether parametric assumptions were met as is detailed in the tables. To 
investigate the relationship between PCT positivity and total DDD, antibiotic receipt at 48 
hours post-diagnosis and meropenem prescription, linear and logistic regression models 
were explored adjusting for demographic confounders (age, sex, ethnicity and 
comorbidities). Regression model assumptions were examined, and appropriate adjustments 
made. All p-values presented were two-sided, and estimates provided with a 95% 
confidence interval (CI). All statistical analyses were performed in Stata version 16.1 
(StataCorp 2019. Stata Statistical Software: Release 16. College Station, TX: StataCorp 
LLC.) 
 
RESULTS 
Study Population 
A total of 368 patients met the eligibility criteria and were included in the analysis; overall 
60% were male, with a median age of 75. Of these, 218 (59%) had a PCT level of ≤0.25 
(negative) and 150 (41%) had a level of >0.25 (positive). Patient demographics and 
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comorbidities stratified by PCT results are available in Table 1. There was no significant 
difference in demographics between the two groups in terms of age, sex, BMI or ethnicity. 
Comorbidities between the two groups were also similarly distributed with the exception of 
malignancy, which was more common in the PCT negative group. There were no pregnant 
women in the cohort. 
Compliance with Guideline 
Of those patients with a negative PCT, 73 (33%) were on antibiotics 48 hours after their 
COVID-19 diagnosis compared to 126 (84%) with a positive PCT (p<0.001) suggesting good 
compliance with the guideline (Table 2). 
Antibiotic Usage 
Data on total DDD of antibiotics received in the 28-day follow-up period and DDD per 
evaluable day are presented in Table 2 and Figure 2. Patients with a negative PCT received 
significantly fewer DDDs of antibiotics (both total and per evaluable day) than those with 
positive PCT with a median DDD of 3.0 vs 6.8 (p<0.001). Due to the log-normal distribution 
of total DDD, a log transformation was performed on the values (after adding the smallest 
non-zero value of 0.17 to ensure patients with a total DDD of zero were included). Therefore, 
a log-linear model was computed in order to explore the relationship with PCT positivity after 
adjusting for demographic confounders (comorbidities, age, sex, ethnicity) to ensure 
regression assumptions were met. A statistically significant relationship between PCT and 
total DDD remained after accounting for these confounders; on average a person with 
PCT>0.25 had almost three times as many DDDs of antibiotics compared to those ≤0.25 
(coefficient 2.72, 95%CI: 2.03, 3.62, p<0.001) (Supplementary Table 1).  
Patient 28-Day Outcomes 
Over the 28-day follow-up period, 116 (32%) of the included patients died, 229 (62%) were 
discharged and 23 (6%) were still in hospital. Median length of stay was 8.35 days. 47 (13%) 
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were admitted to intensive care, and of these, 32 (68%) were intubated and ventilated. The 
PCT, age and 28-day mortality distribution of the patients are illustrated graphically in Figure 
1. In the PCT negative group, 62 (28%) patients died compared to 54 (36%) of those with a 
positive PCT (p=0.021), and 19 (9%) were admitted to ITU, compared with 28 (19%) of the 
positive PCT group (p=0.007); Table 2. 
Meropenem was the only carbapenem used in the study population. With specific reference 
to meropenem consumption, positive PCT was associated with a 3-fold increase in the odds 
of receiving any meropenem during the course of the admission (OR= 3.16, 95% CI: 1.50, 
6.65, p=0.002) after adjusting for demographic confounders (Supplementary Table 2). There 
was also a statistically significant association between receipt of antibiotics at 48 hours after 
COVID-19 diagnosis and receipt of meropenem (OR=3.63, 95% CI: 1.53,8.63, p=0.003). 
(Supplementary Table 3).  
Data on the potential adverse consequences of antibiotic usage are presented in Table 2. 
With the exception of hospital or ventilator associated pneumonia, adverse events were all 
uncommon and none were significantly different between PCT positive and negative groups.  
 
DISCUSSION 
This observational study supports the hypothesis that implementation of a local guideline 
advising against the use of antibiotics for patients with confirmed COVID-19 and a PCT level 
≤0.25, leads to reduced antibiotic consumption without negative impact on patient 28-day 
outcome. 28-day mortality figures in this study (28% PCT ≤ 0.25, 36% PCT > 0.25) are 
similar to data published by the ISARIC consortium, the largest COVID-19 patient registry in 
the UK, in which 7080 of 19983 (35.4%) patients for whom outcome data was available died 
[5]. To our knowledge, this is the first study reporting data from the use of PCT as an 
antimicrobial stewardship tool in patients with COVID-19 and supports its use in this context. 
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Previous studies have demonstrated that procalcitonin-guided therapy in lower respiratory 
tract infections substantially reduces antibiotic use without compromising outcome [22-24], 
including in the critically ill [25]. Although some studies have excluded immunocompromised 
patients when evaluating PCT, others have shown that a rise in the biomarker correlates 
with bacterial infection [26, 27]. Drawbacks of PCT-guided therapy include the potential for 
false negative results in localised infection such as empyema, in atypical infection – and in 
the context of renal replacement therapy [28, 29]. As it may take 24-48 hours for PCT to 
reach its peak, false negatives may be seen if samples are taken early in the course of 
infection [30, 31]. PCT levels also fall by 50% every 24-36 hours [31] and false negatives 
may occur in patients due to resolution of infection. It is important, therefore, that 
interpretation of PCT is made in the context of other laboratory and clinical findings [17]. 
 
PCT results can be obtained rapidly from a readily obtained sample. This presents a major 
advantage over respiratory tract culture results, which are challenged by the inability to 
obtain adequate sample, slower turnaround times and insensitivity. Sputum culture has been 
shown to reveal a definitive diagnosis in less than 20% of cases of community-acquired 
pneumonia [32]. Clinical uncertainty, combined with this diagnostic insensitivity, further 
compromised following initiation of antibiotics, has the potential to provoke unnecessary 
antibiotic usage and consequent short- and long-term morbidity in patients without bacterial 
infection. 
 
The adopted PCT threshold of 0.25 was intentionally conservative and it may be that a 
higher threshold can be adopted safely, which would lead to a further reduction in antibiotic 
usage in patients with COVID-19. 
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This higher mortality seen in the PCT >0.25 group supports those of other authors, 
demonstrating an association between higher PCT values and severe disease or death [33, 
34]. It is possible that higher PCT in these patients reflects bacterial superinfection, which 
increases the production of PCT from non-thyroidal sources through the interplay of 
interleukin (IL)-1β, tumor necrosis factor (TNF)-α and IL-6, whereas viral infections result in a 
rise in interferon (INF)-γ which inhibits PCT synthesis [16]. It is also possible that PCT is 
raised in severe COVID-19 disease independent of bacterial infection, which would open the 
possibility of further improvements in antimicrobial stewardship. 
 
Many of the advances in medicine that have occurred over the past 75 years have been 
made possible because of the effectiveness of antibiotics to prevent or treat infective 
complications. Antimicrobial resistance (AMR) poses a major threat to human health and, if 
unchecked, it is estimated that 10 million deaths may be attributable to AMR by 2050. 
Reducing the unnecessary use of antibiotics is a key component to mitigating this risk. The 
risk of severe COVID-19 disease increases with age and the elderly are also at greatest risk 
of the adverse consequences of excessive antibiotic use [35].  
 
Numerous metrics exist for the measurement of antibiotic consumption, each with their own 
strengths and weaknesses [21]. World Health Organisation Defined Daily Doses have the 
advantage that they are standardised and, at institution level, can be assessed from 
procurement records without recourse to individual prescribing data. They do, however, have 
several drawbacks. They do not factor in exposure equivalent dose adjustments such as 
those that occur in renal or liver dysfunction, and combination therapy results in elevation of 
the DDDs received which may correlate poorly with relative effects on host ecology and 
adverse consequences of therapy. Finally, they are based on usual prescribing patterns and 
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therefore markedly different DDD may apply to different settings or routes of administration 
of the same drug [36]. This latter weakness was addressed in our study through the use of 
the parenteral DDD for those drugs where there was a difference. We also assessed days of 
treatment (DOT), which may be a more relevant metric from a stewardship perspective and 
again this was found to be significantly lower in the negative PCT group. 
 
We also demonstrated a 3-fold increase in the odds of carbapenem prescription in those 
with a positive PCT. This is important in the context of the increasing global incidence of 
carbapenemase-producing Enterobacteriales and is likely to be a direct consequence of 
increased initial antibiotic usage and a concern that this had induced resistance leading to 
prescription of broader spectrum agents for any subsequent indication and despite the fact 
that isolation of ESBL or AmpC positive organisms occurred no more frequently in this 
group. The impact of early antimicrobial therapy on later prescription of broad spectrum 
agents is supported by the association between antibiotic use at 48 hours and subsequent 
meropenem use, which was also statistically significant. 
 
The limitations of our study include the fact that it is from a single centre and retrospective in 
design. However, patients were recruited systematically from the beginning of the epidemic 
locally until a date which was defined in advance and which preceded the introduction of 
routine COVID-19 testing of all admissions regardless of symptoms. It is possible that some 
patients may have been readmitted to other regional hospitals, but this is felt unlikely as the 
catchment area of STHNFT is well-defined and there is limited geographical overlap with 
neighbouring trusts. 
 
 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted July 2, 2020. .https://doi.org/10.1101/2020.06.29.20136572doi: medRxiv preprint 
12 
 
CONCLUSIONS 
This study has demonstrated that procalcitonin level can be a useful tool in the assessment 
of bacterial co-infection of COVID-19 patients, and can safely reduce unnecessary antibiotic 
usage and its associated adverse consequences. 
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Table 1. Baseline demographics details of patients stratified by procalcitonin level 
Procalcitonin level 
(ng/ml) 
 ≤0.25 >0.25 Total p-value 
      
Total No (%)  218 (59) 150 (41) 368 (100)  
      
Age at admission     
  Median (IQR) 75 (61-84) 74 (60-82) 75 (60-83) p=0.417
$
 
Age 18-39 13 (6) 9 (6) 22 p=0.849
#
 
40-49 13 (6) 6 (4) 19 
50-59 26 (12) 22 (15) 48 
60-69 32 (15) 27 (18) 59 
70-79 51 (23) 33 (22) 84 
80+ 83 (38) 53 (35) 136 
      
Sex Male 123 (56) 98 (65) 221 p=0.086* 
Female 95 (44) 52 (35) 147 
      
BMI (n=330) <20 16 (8) 9 (7) 25 p=0.885* 
20-25 51 (26) 40 (30) 91 
25-30 66 (34) 44 (33) 110 
30+ 62 (32) 42 (31) 104 
      
Ethnicity White 172 (79) 112 (75) 284 p=0.428
#
 
Black 13 (6) 13 (9) 26 
Asian 11 (5) 5 (3) 16 
Mixed 1 (0) 1 (1) 2 
Other 3 (1) 3 (2) 6 
Not stated 11 (5) 14 (9) 25 
Missing 7 (3) 2 (1) 9 
      
Any comorbidity No 38 (17) 31 (21) 69 p=0.435* 
Yes 180 (83) 119 (79) 299 
      
Hypertension No 140 (64) 96 (64) 236 p=0.965* 
Yes 78 (36) 54 (36) 132 
      
Diabetes (1 or 2) No 154 (71) 110 (73) 264 p=0.573* 
Yes 64 (29) 40 (27) 104 
      
Cardiovascular 
disease 
No 134 (61) 101 (67) 235 p=0.250* 
Yes 84 (39) 49 (33) 133 
      
Asthma No 195 (89) 134 (89) 329 p=0.972* 
Yes 23 (11) 16 (11) 39 
      
Malignancy No 183 (84) 140 (93) 323 p=0.007* 
Yes 35 (16) 10 (7) 45 
      
Immunosuppressed No 199 (91) 136 (91) 335  p=0.839* 
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Yes 19 (9) 14 (9) 33 
      
Chronic lung 
disease 
No 177 (81) 122 (81) 299 p=0.973* 
Yes 41 (19) 28 (19) 69 
      
Chronic renal 
impairment 
No 192 (88) 125 (83) 317 p=0.196* 
Yes 26 (12) 25 (17) 51 
      
Pregnancy No 218 (100) 150 (100) 368 N/A 
Yes 0 (0) 0 (0) 0 
 
# Fishers Exact test; $ Mann-Whitney U test; * Chi-square test; IQR= Inter-Quartile Range; BMI= Body Mass 
Index 
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Table 2. Antibiotic use and 28 day outcomes in patients stratified by procalcitonin level 
Procalcitonin 
level (ng/ml) 
 ≤0.25 >0.25 Total p-value 
      
Total (%)  218 (59) 150 (41) 368 (100)  
      
Clinical Outcomes     
28 day 
outcome 
Died 62 (28) 54 (36) 116 (32) p=0.021
#
 
Discharged 147 (67) 82 (55) 229 (62) 
Still in 
hospital 
9 (4) 14 (9) 23 (6) 
      
Intubated No 207 (95) 129 (86) 336 (91) p=0.004
#
 
Yes 11 (5) 21 (14) 32 (9)  
      
Admitted to 
ITU 
No 199 (91) 122 (81) 321 (87) p=0.007
#
 
Yes 19 (9) 28 (19) 47 (13)  
      
Length of stay     
  Median (IQR) 8.7 (4.9-15.3) 9.0 (5.9-18.8) 8.9 (5.3-16.1) p=0.054
$
 
      
Antibiotic outcomes     
Total DDD received     
  Median (IQR) 3.0 (0.3-6.3) 6.8 (3.6-10.4) 4.2 (1.3-8.3) p<0.001
$
 
      
Total Antibiotic DOT     
  Median (IQR) 2 (0-5) 5 (4-9) 5 (1-7) p<0.001
$
 
      
DDD received/evaluable day     
  Median (IQR) 0.14 (0.02-
0.31) 
0.37 (0.19-
0.76) 
0.23 (0.08-
0.48) 
p<0.001
$
 
     
Days of treatment per evaluable day to day 28   
  Median (IQR) 0.11 (0.00-
0.25) 
0.32 (0.18-
0.60) 
0.18 (0.04-
0.39) 
p<0.001
$
 
      
Infective complications      
HAP/VAP No 190 (87) 127 (85) 317 p=0.497* 
Yes 28 (13) 23 (15) 51  
      
ESBL/AmpC 
isolation 
No 213 (98) 148 (99) 361 p=0.705
#
 
Yes 5 (2) 2 (1) 7  
      
MRSA No 218 (100) 149 (99) 367 p=0.408
#
 
Yes 0 (0) 1 (1) 1  
CDAD Yes 0(0) 0(0) 0(0)  
 
# Fishers Exact test; $ Mann-Whitney U test; * Chi-Square test; DDD= Defined Daily Dose; DOT=Days Of 
Treatment; IQR= Inter-Quartile Range; ITU= Intensive Treatment Unit; HAP= Hospital-Acquired Pneumonia; 
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VAP= Ventilator-Associated Pneumonia; ESBL= Extended Spectrum Beta Lactamase; MRSA= Methicillin-
Resistant Staphylococcus aureus. CDAD= Clostridioides difficile associated disease. 
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Figure 1: Mortality outcomes for positive and negative PCT groups stratified by age 
 
 
 
 
 
 
 
 
 
 
Figure 2. Antibiotics consumption as demonstrated by average DDD & average meropenem 
DDD between positive and negative PCT groups, stratified by age 
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